Dr. Carey Anders on Exclusion of Patients With Brain Metastases From Clinical Trials

Video

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials. Anders cites one major frustration with this exclusion being that some of the drugs being tested in clinical trials may be able to penetrate into the central nervous system.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Understanding Patient Distress via EHR in Community Oncology

Understanding Patient Distress via EHR in Community Oncology

Jordyn Sava
May 22nd 2025
Article

Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Biomarker Testing Expands in Metastatic Bladder Cancer

Biomarker Testing Expands in Metastatic Bladder Cancer

Jordyn Sava
May 21st 2025
Article

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

AI Predicts Prostate Cancer Prognosis Fairly Across Races

AI Predicts Prostate Cancer Prognosis Fairly Across Races

Jordyn Sava
May 20th 2025
Article

Mack Roach III, MD, discussed a study on artificial intelligence’s generalizability for prostate cancer across racial groups.

Read More

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma

Jordyn Sava
May 20th 2025
Article

Ashraf Z. Badros, MBChB, discussed the results from the AURIGA trial of maintenance therapy with daratumumab and lenalidomide in newly diagnosed multiple myeloma.

Read More